PerkinElmer, Inc Bank of America Merrill Lynch Global Healthcare Conference Andy Wilson, CFO May 13, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH 2014 PerkinElmer
FACTORS AFFECTING FUTURE PERFORMANCE & NON-GAAP FINANCIAL MEASURES This presentation contains "forward-looking" statements which are statements relating to future events. These statements include those relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forwardlooking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These uncertainties may cause our actual future results to be materially different than those expressed in our forward looking statements. A detailed description of these risk factors can be found under the caption Risk Factors in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation. In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-gaap financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are available on the Financial Information section of our website at www.perkinelmer.com. 2
O U R M I S S I O N IMPROVING THE HEALTH AND SAFETY OF PEOPLE AND THE ENVIRONMENT $2.2 BILLION IN SALES 20% EBITDA 7,700 EMPLOYEES 3
Business segments ENVIRONMENTAL HEALTH HUMAN HEALTH RESEARCH DIAGNOSTICS 38% 33% 29% 4
Geographic and product split 49% THE AMERICAS 27% EMEA 24% ASIA PACIFIC INSTRUMENTS 41% CONSUMABLES 24% SOFTWARE/SERVICE 35% 5
STRONG PORTFOLIO WITH LEADING POSITIONS FOCUSED ON CATEGORY LEADERSHIP 75% Of revenue From Products with Top 3 Market Position 6
At PerkinElmer We Provide Answers Environmental Health Human Health Is the water clean? Is my food safe? How healthy is the air I breathe? Is my baby healthy? Is the blood supply safe? Are our drug candidates showing efficacy? 7
ENVIRONMENTAL HEALTH 8
Environmental Health Food Water Chemical Air Market leading positions: Detection & analytical techniques: Inorganic analysis Protein analysis in grain Materials characterization Global market trends: Growing demand for food supply chain security Inadequate supply of clean water driving increased monitoring Regulatory changes Social Media pressuring increase in air quality Monitoring 9
SOLVING CUSTOMER NEEDS A C L E A N E R A N D S A F E R E N V I R O N M E N T Last year, our detection solutions are used to analyze approximately 2.25B AIR, WATER & SOIL SAMPLES, reducing the risk of contaminants. 10
SOLVING CUSTOMER NEEDS Identifying the highest quality grain, ending up in bread on our tables Using Ensuring Perten s the quality portable of nearinfrared throughout grain analyzers the entire to grain measure value crops chain protein levels 11
RESEARCH 12
Research Pre-Clinical Drug Discovery Translational Research Informatics Market leading position: Optical in vivo imaging Life Science Informatics Multi-vendor lab management High content cellular screening and multi-label detection NGS sample prep automation Global market trends: Pharma stabilizing, biotech continuing to grow Focus shifting from basic to translational research OECD funding declining but shifting to China 13
SOLVING CUSTOMER NEEDS M O R E E F F E C T I V E M E D I C I N E S Our technologies and expertise were instrumental in the development of... 22 of the NEWEST THERAPUTIC DRUGS 14
DIAGNOSTICS 15
Diagnostics Screening Testing Market leading position: Newborn and prenatal screening Cord blood storage Flat panel detectors for digital x-ray system Global market trends: Population growth with expanding middle class Increasing demand for expanded testing in emerging markets Imaging Earlier detection of disease Conversion to digital imaging 16
SOLVING CUSTOMER NEEDS HEALTHIER BABIES Our newborn screening technologies have H E L P E D S C R E E N 450M BABIES worldwide to date for a variety of life-threatening diseases. 17
INNOVATION THAT EXTENDS OUR EXISTENCE Enabling the science of sustaining life Food Quality & Safety Air & Water Monitoring Chemical & Material Analysis Enabling Capabilities Detection Imaging Informatics Services Maternal Health Newborn Screening Diagnostics & Research Drug Discovery 18
Financial Performance REVENUE Adjusted EPS $2.24B CAGR 8% $2.47 CAGR 19% $1.55B $1.04 2009 2014 2009 2014 19
Strong global company Leading market positions in attractive end markets Dedicated to making a difference 20